Articles by James C. Greenwood - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by James C. Greenwood

James C. Greenwood


Jim Greenwood is president and CEO of the Biotechnology Industry Organization, 1201 Maryland Ave. SW, Suite 900, Washington, DC 20024, tel. 202.962.9200.

Articles
Prescribing Caution for Biosimilars
April 2, 2013

Sound policies are needed to govern the substitution of interchangeable biologics.

Intellectual Property as the Foundation of Innovation
December 2, 2010

Supportive public policy is needed in order for innovation to flourish.

Delivering on the Promise of Biotechnology
April 2, 2010

The BIO convention, and healthcare reform, could re-energize biotech.

Healthcare Reform Requires Room for Innovation
January 2, 2010

To move from R&D to breakthrough drugs, biotech companies need policies that support innovation.

Progress Made on the Path to Biosimilars
October 2, 2009

BIO supports recent Congressional action toward a 12-year data exclusivity period for innovators.

Biotechnology in 2009
May 2, 2009

The president of BIO proposes the ingredients needed for industry growth.

Industry Leaders Debate Follow-on Biologics Pathway
May 2, 2009

The organizations' presidents discuss market exclusivity, approval processes, and pending legislation.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here